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Abstract
Introduction. Previous studies analyzing ghrelin and obestatin expression in thyroid gland tissue are not unanimous 
and are mostly related to ghrelin. The role of ghrelin and obestatin in the thyroid gland appears very interesting 
due to their probable involvement in cell proliferation. Furthermore, since the thyroid gland is associated with 
the maintenance of energy balance, the relationship between ghrelin, obestatin and thyroid function is worthy 
of consideration. The aim of the study was to assess ghrelin and obestatin immunocytochemical expression in 
nodular goiter (NG), papillary cancer (PTC) and medullary cancer (MTC). 
Material and methods. Analyzed samples included 9 cases of NG, 8 cases of PTC and 11 cases of MTC. The 
analysis of ghrelin and obestatin expression was performed by use of the immunohistochemical (IHC) EnVision 
system and evaluated with filter HSV software (quantitative morphometric analysis).
Results. Quantitative ghrelin expression in MTC cells was higher than in NG (p = 0.013) and correlated nega-
tively with the size of the tumor (r= –0.829, p < 0.05). We did not observe any differences in ghrelin expression 
neither between MTC and PTC nor between NG and PTC. Obestatin immunoexpression pattern in all analyzed 
specimens was irregular and poorly accented. The strongest immunoreactivity for obestatin was demonstrated in 
NG. In MTC obestatin expression was significantly weaker than in NG and PTC (p < 0.05 in both cases). In NG 
the intensity of obestatin immunostaining was significantly higher than that of ghrelin (p = 0.03). Conversely, 
ghrelin expression in MTC was definitely more evident than obestatin immunoreactivity (p < 0.01). There was no 
statistically significant difference between ghrelin and obestatin expression in PTC. No correlations were detected 
between reciprocal tissue expressions of ghrelin and obestatin in the analyzed specimens of NG, PTC or MTC.
Conclusions. The differences between ghrelin expression in NG and MTC suggest that ghrelin may be involved 
in thyroid cell proliferation. The differences between ghrelin and obestatin immunoreactivity in benign and 
malignant thyroid tumors could support the theory of alternative transcription of the preproghrelin gene and 
independent production of ghrelin and obestatin. (Folia Histochemica et Cytobiologica 2015, Vol. 53, No. 1, 19–25)
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Introduction
Ghrelin and obestatin are two peptides encoded by the 
same gene, both postranslationally cleaved from their 
precursor — preproghrelin [1–3]. Ghrelin was initially 
reported as the first endogenous ligand for growth 
hormone secretagogue receptor (GHS-R) and potent 
stimulator of growth hormone release [1, 4]. However, 
further studies revealed that it is a multifunctional hor- 
mone and an essential regulator of metabolic processes [3]. 
Ghrelin is released mainly from gastric mucosa [5], 
but to a lesser extent it was demonstrated also in most 
other central and peripheral tissues [6]. Previous studies 
indicated that the active form of ghrelin is uniquely 
modified (octanoylated at Ser3 residue) [7, 8] and its bio-
logical effects are transduced by ghrelin receptor type 1a 
(GHS-R1a) [3]. Recently, some biological functions 
have also been relegated to des-acyl ghrelin [9]. The role 
of GHS-R1b receptor has not been established yet [3].
The role of the second peptide, obestatin, is still con-
troversial. Studies demonstrating its function (related 
e.g. to food intake or gastric emptying) conflict to those 
that reveal no biological activity of obestatin [10, 11].
Previous studies analyzing ghrelin and obestatin 
expression in thyroid gland tissue are not unanimous 
and are mostly related to ghrelin. Ghrelin has been 
demonstrated in parafollicular cells and medullary 
thyroid cancer cells [12–14]. Ghrelin binding sites have 
been shown in the thyroid [6] and exogenous ghrelin 
uptake in the thyroid gland was demonstrated to be 
notably higher than in other tissues [15].
The role of ghrelin and obestatin in the thyroid ap-
pears very interesting for their probable involvement 
in cell proliferation [16–18]. The relationship between 
thyroid cancer pathogenesis and ghrelin and obestatin 
expression has not been clearly defined. Furthermore, 
since the function of thyroid gland is associated with 
the maintenance of energy balance, the relationship 
between ghrelin, obestatin and thyroid function is 
worthy of consideration [19–24]. 
The aim of the study was to assess both ghrelin 
and obestatin immunocytochemical expression in 
both benign and malignant thyroid tumors (nodular 
goiter, papillary and medullary thyroid cancer) using 
quantitative morphometry. We assumed that ghrelin 
and obestatin expression may be altered in different 
types of thyroid tumors. Furthermore, the potential dif-
ferences may reflect the influence of both peptides on 
the pathogenesis of nodular goiter and thyroid cancer.
Material and methods
Material. Tissue samples were collected from thyroids 
operated due to therapeutic indications. The study was 
approved by the local Ethics Committee and the informed 
consent was obtained from each patient.
Analyzed samples included 9 cases of nodular goiter 
(NG), 8 cases of papillary thyroid cancer (PTC) and 11 cases 
of medullary thyroid cancer (MTC). The clinical data of 
analyzed cases are presented in Table 1. In 4 patients with 
MTC complete result of TNM Classification of Malignant 
Tumors could not be obtained. In 5 patients with MTC and 
3 patients with PTC, the precise information on the size of 
tumors could not be obtained.
Tissue processing and microscopy image analysis. We 
used the archival material that was fixed in buffered 10% 
formalin or Bouin’s fluid and embedded in paraffin using 
the routine procedure. Paraffin sections 5 μm thick were 
placed on the SuperFrost/Plus microscope slides. Staining 
with hematoxylin and eosin (HE) was performed. Patterns of 
HE-stained histological preparations were examined using 
Olympus BH-2 light microscope (Olympus, Tokyo, Japan) 
by two histopathologists.
Immunocytochemical studies. The analysis of ghrelin and 
obestatin expression in thyroid gland was performed by use 
of the new polymer-based immunohistochemical (IHC) 
technique [25]. Rabbit polyclonal antibodies directed against 
human ghrelin (Phoenix Pharmaceuticals, Inc., catalog no. 
H-031-30, Burlingame, California, USA) were employed in 
dilution 1:1,500 and against human obestatin (Phoenix Phar-
maceuticals, Inc., catalog no. H-031-92) in dilution 1:8,000. 
The sections were incubated with these primary antibodies 
overnight at 4°C, then incubated with dextran backbone (atta-
ched to peroxidase — HRP) and secondary biotinylated link 
anti-rabbit and anti-mouse IgG (Dako REALTMEnVisionTM 
Detection System peroxidase/DAB+, Rabbit/Mouse, Dako, 
Glostrup, Denmark) was applied. After subsequent depa-
raffination and rehydration the preparations were boiled in 
Table 1. The clinical characteristics of analyzed patients with different thyroid gland diseases
Female/Male Age TNM scale
(No.) (years, mean ± SD) T1/T2/T3/T4 N0/N1
Nodular goiter 6/3 52.2 ± 12.2 – –
Papillary thyroid cancer 8/0 48.9 ± 16.4 4/1/1/2 5/3
Medullary thyroid cancer 5/6 48.6 ± 16.7 1/3/1/2 4/4
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10 mM sodium citrate buffer (pH = 6.0) in a 700 W microwave 
oven for 18 min (for sections to be stained with anti-ghrelin 
antibodies), washed in phosphate buffer saline (PBS) and 
then subjected to the reaction according to the standard 
procedure. Internal negative control reactions were based 
on substituting specific antibodies with a normal serum of 
a respective species in 0.05 M Tris-HCl, pH 7.6, supplemented 
with 0.1% bovine serum albumin (BSA) and 15 mM sodium 
azide (Sigma-Aldrich, St. Louis, MO, USA). Histological 
slides with ghrelin and obestatin expression were examined 
under an optical Olympus BH-2 microscope coupled to 
a digital camera. Color microscope images were recorded 
using 40 × objective (at least 10 fields in every microscope 
slide with an IHC positive reaction), using LUCIA Image 
5.0 computer software (Nikon, Tokyo, Japan). The positive 
control staining was done on human stomach tissue.
Microscopy image analysis. Quantitative morphometric 
analysis of ghrelin and obestatin tissue expression was done 
by use of HSV Filter software, originally developed and de-
scribed in Department of Bioinformatics and Computational 
Biology, Poznan University of Medical Sciences, Poland [26]. 
We measured the area of IHC reaction and then we calcula-
ted the percentage of the reaction in the relation to the area 
of the whole image (analyzed area of thyroid gland). Such 
evaluation was performed in 10 microscopic fields in each 
patient. Then we calculated the mean value in every patient 
and each studied group of patients (NG, PTC and MTC). 
Statistical analysis. The statistical analysis was performed 
using the Statistica PL vs. 9 software (Statsoft, Inc., Tulsa, 
OK, United States) and appropriate tests. The Kruskal-Wal-
lis test was used to compare the peptides’ IHC expression. 
In case of significant differences, additional analysis was 
performed with a multiple comparison test (Dunn test). The 
Wilcoxon test was used for non-parametric dependent data. 
Correlations between data rows were determined with Spear - 
man’s rank correlation index. The results were accepted 
as significant at the threshold of p £ 0.05.
The results of positive control staining in human stomach 
tissue were not analyzed statistically.
Results
Cellular localization of ghrelin and quantitative 
analysis of ghrelin immunoexpression
Ghrelin immunoreactivity in NG was observed in 
cytoplasm of single thyroid cells and single groups of 
cells (Figure 1A). In PTC cells ghrelin expression was 
observed also in cytoplasm (Figure 1B). The intensity 
of the reaction was irregular by means of unequal 
intensity of IHC reaction in papillary and follicular 
structures, as well as irregular expression in apical and 
basal poles of the cancer cells. The lumen of several 
follicular structures contained parts of cancer cells 
that were also ghrelin-positive. No reaction for ghrelin 
was observed in the stroma. MTC presented strong 
intensity of cytoplasmic expression of ghrelin (Figu- 
re 1C). The stroma of MTC was ghrelin-negative.
The comparative quantitative analysis (Table 2) 
showed that ghrelin immunoexpression was significan-
tly higher in MTC than in NG (p = 0.013). No diffe-
rences were demonstrated in ghrelin expression neither 
between MTC and PTC nor between NG and PTC. 
The immunoexpression of ghrelin in MTC cor-
related negatively with the size of the tumor (r = 
–0.829, p < 0.05). 
There was no correlation between ghrelin expression 
and PTC tumor size (r = 0.4, p > 0.05) (data not shown).
Cellular localization of obestatin and quantitative 
analysis of obestatin immunoexpression
Obestatin expression in all analyzed specimens was 
irregular and poorly accented. Cells presenting obe-
statin immunoreactivity (cytoplasmatic reaction) 
were accompanied by obestatin-negative regions. 
The strongest immunoreactivity for obestatin was 
demonstrated in NG (Figure 1E). The reaction was 
also observed in the colloid; however, it was not taken 
into statistical analysis. 
In PTC, the immunohistochemical reaction for 
obestatin was also irregular and observed in some 
groups of cancer cells (Figure 1F). In MTC obestatin 
expression was barely noticeable (Figure 1G).
The results of quantitative analysis of obestatin 
immunoexpression in the studied tissues showed that 
it was significantly lower in MTC than in NG and 
PTC (Table 2). 
No correlations were found between obestatin 
expression and MTC tumor size (r = –0.49, p > 0.05) 
nor between obestatin expression and PTC tumor size 
(r = –0.1, p > 0.05) (data not shown).
Ghrelin versus obestatin expression
In nodular goiter the immunoreactivity of obestatin 
was significantly higher than that of ghrelin. Conver-
sely, in MTC ghrelin immunoexpression was definitely 
more evident than that of obestatin (Table 2). There 
was no statistically significant difference between 
ghrelin and obestatin immunoexpression in PTC.
Correlation between ghrelin and obestatin expression
Spearman’s rank coefficients analysis for correlation 
between ghrelin and obestatin reciprocal immuno-
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expression in patients with NG, PTC and MTC reve-
aled that tissue expression of ghrelin and obestatin 
did not correlate in any of the analyzed groups (NG: 
r = 0.209, p > 0.05; PTC: r = –0.238, p > 0.05; MTC: 
r = –0.009, p > 0.05). 
Cellular localization of ghrelin and obestatin  
in positive and negative control samples
In positive control samples from the human stomach 
there were many cells immunopositive for ghrelin and 
obestatin (Figure 1D and 1H). 
Figure 1. Immunohistochemical expression of ghrelin in nodular goiter (A), thyroid papillary cancer (B), and thyroid 
medullary cancer (C). Immunohistochemical expression of obestatin in nodular goiter (E), papillary cancer (F), and me-
dullary cancer (G). Human stomach tissue was used as positive control for ghrelin (D) and obestatin (H) immunostaining. 
Sections were counterstained with hematoxylin. Bar, 40 μm
A E
B F
C G
D H
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No staining was observed in negative controls of 
NG, PTC and MTC (not shown).
Discussion
The first reports of ghrelin expression in the thyroid 
were related to parafollicular cells. In 2001 Kanamoto 
et al. suggested that MTC cells produce ghrelin [12]. 
The authors demonstrated by Northern blot analysis 
that TT cells (stabilized cell lines derived from MTC) 
express preproghrelin mRNA. Radioimmunological 
analysis revealed that ghrelin is present in the extracts 
from TT cells and immunoreactivity was shown in cell 
cytoplasm [12]. Ghrelin was even proposed as a new 
diagnostic marker of MTC [27]. However, a compa-
rison of plasma ghrelin levels between patients with 
MTC and control subjects did not reveal significant 
difference [27]. Further studies showed that ghrelin 
is also present in parafollicular cells of a healthy thy-
roid [13]. In our study immunocytochemical expres-
sion of ghrelin in MTC was significantly higher than 
in benign NG. Nevertheless, its immunoreactivity 
was not significantly stronger than the IHC reaction 
observed in PTC. 
Ghrelin expression in follicular cells is still contro-
versial. Raghay et al. reported that follicular cells are 
ghrelin-negative [13]. The authors noticed that there 
was a strong ghrelin immunoreactivity in parafollicu-
lar cells, and GHS-R1a expression on follicular cells 
may indicate that ghrelin produced in parafollicular 
cells influences follicular cells in a paracrine man- 
ner [13]. Study by Karaoglu et al. demonstrated 
ghrelin expression in follicular cells of Hashimoto 
thyroiditis [28]. Furthermore, it was even considered 
that ghrelin may be present only in follicular cells of 
fetal thyroid glands with no expression in adult thyroid 
glands, as reported by Volante et al. [29]. In the same 
study ghrelin was re-expressed in follicular-derived 
thyroid tumors. 
The differences between ghrelin expression in 
benign and malignant thyroid tumors have not been 
thoroughly characterized. Zhang et al. [30] revealed 
that ghrelin is expressed in thyroid cancer, but not in 
benign thyroid diseases. Volante et al. demonstrated 
ghrelin in papillary, follicular and medullary can- 
cer [29]. On the other hand, Karaoglu et al. [28] de-
scribed poor ghrelin expression in PTC in contrast to 
intense ghrelin immunoreactivity in non-cancerous 
thyroid tissues.
In this study ghrelin expression was noted in nodu-
lar goiter. However, the intensity of the reaction was 
low. In comparison to benign nodular goiter ghrelin 
immunoreactivity was more noticeable in PTC and 
MTC cells (with statistically significant differences 
in case of MTC). The discrepancies between ghrelin 
expression in healthy thyroid, benign thyroid diseases 
and thyroid cancer are worthy of consideration, espe-
cially in view of ghrelin influence on cell proliferation. 
The results of most of the previous studies show that 
ghrelin stimulates the proliferation of normal cell lines 
[18, 31, 32]. However, in the matter of cancer cell lines 
some authors described pro-proliferative properties of 
ghrelin and some demonstrated its anti-proliferative 
action [3, 18, 29]. Cassoni et al. showed that synthetic 
growth hormone secretagogues induce growth-inhibi-
tory effects on cell lines derived from follicular thyroid 
cancers [33]. Similarly, Volante et al. demonstrated 
anti-proliferative effects of ghrelin in the cells lines 
of papillary and anaplastic thyroid cancer analyzed in 
vitro [29]. While inhibition of proliferative processes 
in anaplastic cancer cell lines required higher ghre-
lin concentrations than PTC, the authors suggested 
that ghrelin receptors in anaplastic cancer are either 
modified or their ability to bind ghrelin is disturbed.
Table 2. Comparison of quantitatively assessed ghrelin and obestatin immunoexpression in nodular goiter (NG), medulla-
ry (MTC) and papillary thyroid cancer (PTC)
No. Mean Median Min Max SD Statistical significance
Ghrelin
NG 9 2.04 1.39 0.01 4.95 1.87 NG vs. MTC: p = 0.013
MTC 11 15.74 16.29 0.86 43.50 11.94 NG vs. PTC — NS
PTC 8 11.47 5.03 0.97 33.38 11.81 MTC vs. PTC — NS
Obestatin
NG 9 6.06* 4.36 0.91 13.24 4.51 NG vs. MTC: p < 0.001
MTC 11 0.74** 0.10 0.00 3.27 1.20 NG vs. PTC — NS
PTC 8 3.22 3.03 0.30 5.66 2.00 MTC vs. PTC: p = 0.04
Data show area fraction (%) of the IHC reaction in analyzed area of thyroid gland. Abbreviations: min and max — minimal and maximal values, 
respectively; NS — statistically non-significant. The Kruskal-Wallis test was used to compare the peptides’ immunohistochemical expression. In 
case of significant differences, additional analysis was performed with a multiple comparison test (Dunn test) (see Material and methods). *signi-
ficantly higher immunoexpression of obestatin than ghrelin in NG, p < 0.05; **significantly lower immunoexpression of obestatin than ghrelin in 
MTC, p < 0.01
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Interestingly, several studies revealed that ghrelin 
expression in cancer cells is decreased in comparison 
to healthy tissue. This was observed in thyroid, sto-
mach, esophagus, pancreas and renal cell carcinoma 
[28, 34–36]. Therefore, if pro-proliferative properties 
of ghrelin should be considered, it could be discussed 
if its absence or poor expression in cancer tissue pro-
vides protection from further growth.
The second peptide — obestatin was demonstrated 
in our study mainly in NG and PTC. The reaction for 
obestatin in MTC was poor. The expression of obesta-
tin and its potential role in the thyroid gland still needs 
to be defined. In previous studies Volante et al. [37] 
demonstrated obestatin in medullary, papillary, fol-
licular and poorly differentiated thyroid cancer. The 
authors observed obestatin immunoreactivity mostly 
in ghrelin-positive areas, which showed more intense 
and a diffuse pattern of staining. There was no obe-
statin expression in normal thyroid parenchyma. On 
the contrary, Karaoglu et al. demonstrated obestatin 
expression in healthy thyroid, Hashimoto thyroiditis 
and PTC without evident differences in the intensity 
of reaction [28]. 
In this study obestatin immunoreactivity was ob-
served in benign NG, as well as cancer cells. However, 
the intensity of immunohistochemical expression was 
poor. Obestatin-positive cells were accompanied by 
regions without any immunoreactivity.
The differences between ghrelin and obestatin 
immunoreactivity in benign and malignant thyroid 
tumors could support the theory of alternative tran-
scription of pre-proghrelin gene and thus of indepen-
dent production of ghrelin and obestatin [38]. In this 
study there was no correlation between ghrelin and 
obestatin immunoreactivity in any of the analyzed 
groups. Moreover, a strong reaction for ghrelin was 
accompanied by poor obestatin expression in MTC 
and, on the other hand, obestatin immunoreactivity in 
NG was significantly higher than ghrelin expression.
The relationship between ghrelin, obestatin and 
thyroid dysfunction (hyperthyroidism, hypothyro-
idism) is also worth further studies. Recently, the new 
peptide of probable influence on body metabolism 
— irisin has been studied in different thyroid func-
tional states [39]. Hopefully the association between 
thyroid hormones and their modulators will be soon 
identified.
Conclusions
Ghrelin is expressed in PTC and MTC cells and, to 
a lesser extent, in NG. The differences between ghrelin 
expression in NG and MTC suggest that ghrelin may 
be involved in thyroid cell proliferation. The immu-
nohistochemical reaction for obestatin in NG and 
thyroid cancer cells is poor and irregular. In light of 
the common origin of ghrelin and obestatin, it is inte-
resting that in MTC and NG the intensity of reaction 
for both peptides was different. The potential role of 
obestatin in thyroid gland needs further investigation.
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